Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:
“The 2026 Society for Immunotherapy of Cancer (SITC)’s Biotech Strategic Meeting at the NYSE brings investors and leaders from biotechnology, biopharma, academia, and regulatory agencies for high-level strategic dialogue on the future of cancer immunotherapy.
Friday, June 26 at the NYSE
Keynote:
‘Trends and Data in the IPO Market’
Daina Graybosch, PhD – Leerink Partners
Keynote:
‘IO Dealmaking and Partnership Trends’
Andrew Baum, MD
View the schedule and register.
Space is Limited!”
Other articles about Immunotherapy on OncoDaily.